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H. pylori exploits and manipulates innate and
adaptive immune cell signaling pathways to
establish persistent infection
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Abstract
Persistent infection with the gastric bacterial pathogen Helicobacter pylori causes gastritis and predisposes carriers
to a high gastric cancer risk, but has also been linked to protection from allergic, chronic inflammatory and
autoimmune diseases. In the course of tens of thousands of years of co-existence with its human host, H. pylori has
evolved elaborate adaptations that allow it to persist in the hostile environment of the stomach in the face of a
vigorous innate and adaptive immune response. For this review, we have identified several key immune cell types
and signaling pathways that appear to be preferentially targeted by the bacteria to establish and maintain
persistent infection. We explore the mechanisms that allow the bacteria to avoid detection by innate immune cells
via their pattern recognition receptors, to escape T-cell mediated adaptive immunity, and to reprogram the
immune system towards tolerance rather than immunity. The implications of the immunomodulatory properties of
the bacteria for the prevention of allergic and auto-immune diseases in chronically infected individuals are also
discussed.
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Innate immune receptor recognition of H. pylori
Innate immune cells as well as epithelial cells forming a
first barrier to infection detect invading pathogens via
their conserved microbial structures, the so-called patho-
gen-associated molecular patterns (PAMPs). Examples of
PAMPs include microbial nucleid acids, and cell wall and
flagellar components such as peptidoglycan, lipopolysac-
charide (LPS), lipoproteins and flagellins [1]. PAMPs are
recognized by at least four distinct classes of innate
immune or pattern recognition receptors (PRRs) that are
present either on cytoplasmic and endosomal membranes
(Toll-like receptors, TLRs, and C-type lectin receptors,
CLRs) or in the cytosol (NOD-like receptors, NLRs, RIG-
like receptors, RLRs). Generally speaking, the ligation
of TLRs, CLRs or RLRs results in the activation of
pro-inflammatory transcription factors in the nucleus; in
contrast, most NLRs are involved in the assembly of
multi-protein complexes termed “inflammasomes”,
which process pro-IL-1b and pro-IL-18 to generate the
mature, bioactive cytokines [2] (summarized in Figure 1).
PRRs are present not only on hematopoietic cells, but
also on gastric epithelial cells which form a first line of
defense against H. pylori infection [3,4]; therefore, many of
the seminal studies in the field have focused on examining
H. pylori recognition by epithelial cells. In particular,
TLR4, 5 and 9 have been detected immunohistochemically
on gastric epithelial cells in H. pylori-infected as well as
uninfected patients, which in principle allows these cells to
sense and respond to the infection [3,4]. Interestingly,
H. pylori differs from other gastrointestinal pathogens in
that it has evolved to largely avoid recognition by PAMPs.
H. pylori flagellin is a poor ligand of TLR5 [5] due to
mutations in the TLR5 recognition site of the N-terminal
D1 domain of flagellin [6]. Indeed, mutating residues 89-
96 of the strongly recognized Salmonella flagellin to the
corresponding H. pylori flaA sequence abolishes TLR5
recognition [6]. The bacterium’s LPS consists predomi-
nantly of the tetra-acylated lipid A variety, which is known
to exhibit 1000-fold reduced bioactivity as compared to
E. coli LPS [7]. H. pylori LPS activates the TLR4/MD-2
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complex, but this has only been shown in vitro in cells
overexpressing the complex [4]. Rather than being a
strong TLR4 ligand, H. pylori LPS is thought to activate
TLR2 on gastric epithelial cells, but again this has only
been demonstrated in vitro using ectopic expression of the
TLR [8,9]. Animal and cell culture experiments suggest
that TLR2 ligands (LPS or other) indeed exist in H. pylori
and related Helicobacter species [9-11], and can bind to
TLR2 and activate NF-B in epithelial cells [9]. However,
the net effects of TLR2 ligation are anti-rather than pro-
inflammatory in vivo as evidenced by lower H. pylori colo-
nization levels and more severe immunopathology in
gene-targeted mice lacking TLR2 [11]. While H. pylori
DNA activates TLR9 expressed on dendritic cells (DCs) in
vitro [10], TLR9-/- mice do not differ from wild type mice
in their ability to control H. pylori infections [11].
H. pylori’s 5’-triphosphorylated RNA can be sensed by the
intracellular receptor RIG-1 and triggers type I interferons
in DCs [10], but the role of this response in the control of
the infection and the infection-associated pathology has to
date not been explored. H. pylori further possesses fucosy-
lated ligands for the C-type lectin receptor DC-SIGN [12].
However, in contrast to the mannosylated DC-SIGN
ligands of Mycobacterium tuberculosis, which activate sig-
naling downstream of DC-SIGN and trigger pro-inflam-
matory cytokine production, the DC-SIGN ligands of
H. pylori actively dissociate the signaling complex down-
stream of this C-type lectin to suppress pro-inflammatory
cytokine production [12]. The PRRs involved in sensing
and responding to H. pylori are summarized in Figure 1.
Taken together, the data available to date provide ample
evidence of the impressive ability of H. pylori to avoid
Figure 1 Host innate immune receptors and signaling networks known or believed to participate in H. pylori recognition. Toll-like
receptors (TLRs), NOD-like receptors (NLRs), RIG-like receptors (RLRs), and C-type lectin receptors (CLRs) are expressed on the cell surface, in the
endosomes, or in the cytosol of various types of immune cells. Their activation by specific pathogen-associated molecular patterns/ligands
induces the expression of cytokine genes or results in the activation of caspase-1 and processing of IL-1b and IL-18. TLR2 and TLR9 recognize H.
pylori LPS, lipoproteins and DNA, respectively [8-11]; in contrast, H. pylori LPS and flagellins are poor ligands of TLR4 and TLR5, respectively
(indicated by dotted lines) [5,7]. The RIG-I-dependent recognition of H. pylori 5’-triphosphorylated RNA in dendritic cells has been reported to
induce expression of type I interferons [10]; fucosylated H. pylori ligands for the CLR DC-SIGN have been described, but appear to repress rather
than activate signaling downstream of this surface-exposed CLR [12]. NOD1 recognizes H. pylori peptidoglycan and activates the transcription
factors NF-B and AP1 [16,17], and also triggers the production of type I interferons [21]. Comparatively little is known regarding additional
possible NLR ligands (indicated by question marks). Conceivable, but unconfirmed H. pylori NLR ligands include flagellins (for NAIP5 and IPAF)
and toxins (NALP3), which would activate the inflammasome and lead to the secretion of mature IL-1b and IL-18. Adapted from [1].
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innate immune detection by the host’s arsenal of PRRs,
thereby preventing innate and adaptive immunity and
ensuring its persistence.
NOD1 signaling contributes to anti-H. pylori
defense mechanisms
As mentioned earlier, the NLRs NOD1 and NOD2 recog-
nize peptidoglycan metabolites of various pathogenic
bacteria [13,14] and induce the transcription factor NF-
B to activate immune response genes [15]. Indeed,
NOD1 was among the first PRRs shown to recognize an
H. pylori-derived PAMP, i.e. its peptidoglycan [16], and
has since attracted considerable attention. In their initial
study, Ferrero and colleagues showed that peptidoglycan
recognition by NOD1 was dependent on the expression
of a functional Cag pathogenicity island (PAI)-encoded
type IV secretion system (T4SS) and resulted in NF-B
activation [16]. More recently, the same group demon-
strated that MAP kinases and the AP1 transcription fac-
tor were also activated upon peptidoglycan recognition
by NOD1 [17]. NOD1 activation by cagPAI+ H. pylori
was further shown to be required for production of beta-
defensins by gastric epithelial cells, which contributes to
the bactericidal activity of cell culture supernatants
against H. pylori [18]. H. pylori peptidoglycan delivery to
cytosolic NOD1 via the T4SS occurs at cholesterol-rich
microdomains referred to as lipid rafts, which contain
high local concentrations of the T4SS receptor a5b1
integrin [19]; both cholesterol and a5b1 integrin are
required for the T4SS-dependent delivery of peptidogly-
can [19]. Although it was initially believed that peptido-
glycan delivery occurs exclusively via the T4SS [16],
Kaparakis et al. now provide evidence that outer mem-
brane vesicles prepared from cagPAI- H. pylori can also
target peptidoglycan to cytosolic NOD1, and that intra-
gastric delivery of peptidoglycan via outer membrane
vesicles is sufficient to trigger innate and adaptive
immune responses in mice [20].
A novel pathway downstream of NOD1 was recently
elucidated in an elegant study by Watanabe et al., who
were able to link NOD1 signaling to the production of
type I interferons and to the control of H. pylori infection
[21]. Upon binding to its specific ligand, iE-DAP, NOD1
was shown to induce the sequential activation of the serine
threonine kinase RICK, the TNF-associated factor 3
(TRAF3), the kinases TBK1 and IKKε, and ultimately the
transcription factor IFN regulatory factor 7 (IRF7) [21].
IRF7 in turn induces IFN-b production, which leads to
activation of the heterotrimeric transcription factor com-
plex IFN-stimulated gene factor 3 (ISGF3) and the subse-
quent production of more IFN-b. Mice lacking the IFN-b
receptor exhibit increased susceptibility to H. pylori infec-
tion, thereby phenocopying the defect of NOD1-deficient
mice and suggesting that this pathway participates in host
defenses against H. pylori [21]. The complete pathway is
summarized in Figure 2. The study by Watanabe et al.
refutes previous work showing that Nod1 activation
induces NF-B activity; at least in epithelial cells, the
authors found no or minimal NF-B activation upon
Nod1 ligation by iE-DAP [21]. Another interesting recent
study by Liu et al. showed that NOD1 and NOD2 are tar-
gets of the immunomodulatory glycoprotein olfactomedin
4 (OLFM4) in the context of H. pylori infection [22].
OLFM4 is an NF-B target gene and associates directly
with both NOD proteins, thereby creating a negative feed-
back loop that impairs H. pylori-induced NF-B activation.
OLFM4 knockout mice exhibited reduced H. pylori loads
and enhanced gastric immune cell infiltration compared
to wild type animals, suggesting that OLFM4 acts as nega-
tive regulator of H. pylori-specific, NOD-mediated
immune responses [22].
Inhibition of T-cell signaling and proliferation by
the H. pylori virulence factors VacA and
g-glutamyl-transpeptidase
CD4+ MHC class II-restricted T-cells are absolutely
required for the control of experimental H. pylori infec-
tions and for the development of vaccine-induced protec-
tive immunity [23-25]. It therefore does not come as a
big surprise that H. pylori has evolved virulence factors in
the course of its 60.000+ years of co-existence with the
human host [26] that allow it to suppress T-cell-
mediated immunity. Seminal work by Haas, Cover, Bal-
dari and their co-workers identified the vacuolating cyto-
toxin (VacA) as a key factor in the H. pylori-mediated
inhibition of human T-cells [27-29]. VacA had initially
been identified due to its ability to induce vacuolization
of epithelial cells [30]. Haas, Cover, Baldari and collea-
gues extended these original findings to show that VacA
inhibits cell proliferation by interfering with the T-cell
receptor/interleukin-2 (IL-2) signaling pathway at the
level of the Ca2+-calmodulin-dependent phosphatase cal-
cineurin [27-29]. VacA thus prevents the nuclear translo-
cation of the T-cell transcription factor NFAT, a global
regulator of T-cell responses, resulting in downregulation
of IL-2 gene transcription [27,28]. In subsequent studies,
Haas and co-workers identified b2 (CD18) integrin to be
the relevant receptor for VacA on human T-cells [31].
The authors were able to show that VacA exploits the
recycling of lymphocyte function-associated antigen-1
(LFA-1; an integrin heterodimer on T-cells consisting of
a b2 subunit associated with the CD11a a subunit) to
become internalized by migrating human T-cells. LFA-1-
deficient Jurkat T cells were resistant to vacuolation and
IL-2 modulation, and genetic complementation restored
their sensitivity to VacA [31]. A recent study further
showed that VacA uptake depends on protein kinase C-
mediated serine/threonine phosphorylation events,
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presumably of a specific threonine in the b2/CD18 cyto-
plasmic tail [32].
An alternative mechanism of T-cell suppression has
been proposed by Gerhard and co-workers, who provided
evidence in 2005 that human T-cell proliferation is
blocked by H. pylori without accompanying effects on
NFAT activation or cytokine production [33]. The
authors postulated at the time that a secreted low-mole-
cular-weight protein distinct from VacA arrests antigen-
activated T-cells in the G1 phase of the cell cycle by
interfering with G1 cyclin-dependent kinase activity [33].
The authors later demonstrated through a biochemical
approach that the secreted g-glutamyl transpeptidase
(GGT) of H. pylori is the responsible factor for inhibition
of T-cell proliferation; mutagenesis of GGT abrogated
the inhibitory effect of the bacteria and recombinantly
expressed GGT enzyme showed anti-proliferative activity
[34]. The authors concluded from measuring reduced
levels of c-Myc and phosphorylated c-Raf protein that
GGT induces cell cycle arrest by disrupting the Ras sig-
naling pathway [34].
H. pylori infection induces “tolerogenic” DCs and
regulatory T-cells with suppressive activity
Direct inhibition of T-cells by H. pylori virulence factors
represents a compelling mechanism of immunosuppres-
sion and likely contributes to the bacteria’s persistence in
the human stomach. In addition, several laboratories
have reported lately that H. pylori-specific effector T-cell
responses are under the strict control of regulatory
Figure 2 Schematic of NOD1 signaling pathways. NOD1 activation by its specific ligand iE-DAP activates at least two distinct signaling
pathways. On the one hand, activated NOD1 triggers IFN-b production through the consecutive activation of RICK, TRAF3, TBK1/IKKε and IRF7.
IRF7-dependent IFN-b production leads to the expression of IP-10 and other Th1 cytokines via transactivation of ISGF3 (Stat1-Stat2-IRF9 complex).
On the other hand, NOD1 activation triggers the RICK and IKK-a,b,g complex-dependent activation of NF-B and subsequent production of
proinflammatory cytokines and chemokines such as IL-8. Whether NF-B is indeed activated upon Nod1 ligation in all cell types, including
epithelial cells, remains controversial and will be the subject of future experimentation. Adapted from [56] and [21].
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T-cells (Tregs) in infected humans, and that the deple-
tion of Tregs improves immunological control over the
infection and enhances vaccine-induced protective
immunity in mouse models [35-38]. The degree to which
the infected host generates H. pylori-specific Tregs
appears to depend largely on the age at the time of infec-
tion [35]. Mice that are experimentally infected as adults
with virulent H. pylori harboring the Cag pathogenicity
island-encoded T4SS mentioned earlier rapidly develop
gastritis and gastric cancer precursor lesions manifesting
histologically as atrophic gastritis, intestinal metaplasia
and epithelial hyperplasia [35]. In contrast, mice that are
exposed to H. pylori during the neonatal period are pro-
tected against the development of such lesions, despite
the fact that they are colonized at much higher levels
than their adult-infected counterparts. The difference in
H. pylori colonization and the associated pathology is clo-
sely linked to dramatic differences in local as well as sys-
temic immune responses to the bacteria between the age
groups. Neonatally infected mice develop immunological
tolerance to the infection, which prevents them from
generating H. pylori-specific T-helper responses and pro-
tects them from developing T-cell driven immunopathol-
ogy. H. pylori-specific immunological tolerance depends
on regulatory T-cells; their systemic depletion breaks tol-
erance and sensitizes mice to gastric immunopathology
[35]. Whether immunological tolerance develops in
humans infected early enough with H. pylori remains a
matter of speculation. A study showing that infected chil-
dren, but not adults, preferentially generate regulatory T-
cell responses to the infection argues in favor of the tol-
erance model [39].
Above and beyond their role in preventing immuno-
pathological gastric T-helper responses to the infection,
Tregs are crucial mediators of the protection against
allergen-induced asthma that is conferred by H. pylori
infection in mice [40] and humans [41-44]. In infected
mice subjected to an experimental protocol inducing
airway inflammation and hyper-responsiveness through
sensitization and challenge with ovalbumin, the protec-
tion against asthma can be abrogated by Treg depletion
[40]. Conversely, asthma protection can be transferred
from infected to uninfected mice by highly purified
population of Tregs [40]. The exact mechanism of the
suppression of H. pylori-specific or of allergen-specific
effector T-cells by H. pylori-induced regulatory T-cells
is not well understood; the secretion of suppressive Treg
cytokines such as IL-10 and TGF-b, but also contact-
dependent mechanisms of effector T-cell suppression
can be envisioned. It is of interest to note in this context
that H. pylori infection seems to be inversely correlated
not only with asthma, but also with chronic inflamma-
tory conditions of the small and large intestine. Several
epidemiological studies have pointed out this
association, looking at both ulcerative colitis and
Crohn’s disease patient populations [45,46]. Recent
experimental evidence supports this concept; in a model
of Salmonella typhimurium-induced colitis, concomitant
H. pylori infection alleviated disease symptoms [47].
Protection against this form of colitis was attributed to
reduced Th17 responses in the gut under conditions of
co-infection, and coincided with the production of
immunomodulatory (Treg-derived?) IL-10 in the mesen-
teric lymph nodes of the co-infected mice [47].
Inducible Tregs (iTregs; in contrast to “natural”, thy-
mus-derived nTregs) differentiate in the periphery as a
result of their priming by dendritic cells (DCs) with
“tolerogenic” rather than immunogenic properties [48].
Tolerogenic DCs convert naive T-cells into FoxP3+ Tregs
through antigen presentation in the absence of co-stimula-
tory signals or cytokines, either alone or in combination
with the production of soluble and membrane-bound tol-
erogenic factors such as IL-10, TGFb, retinoic acid, and
programmed death ligands [48,49]. Tolerogenic properties
have been attributed to immature DCs that have taken up
antigen, but have not simultaneously been exposed to TLR
or NLR ligands; such DCs are believed to acquire a semi-
mature state characterized by high levels of MHCII, but
low or no expression of co-stimulatory molecules or pro-
inflammatory cytokines [48,49]. It is tempting to speculate
based on the characteristic paucity of TLR and NLR
ligands that is a hallmark of H. pylori that the pathogen
has evolved precisely to avoid DC maturation, and to
thereby promote Treg rather than T-effector responses.
Experimental evidence for such Treg skewing comes from
in vitro experiments with bone-marrow-derived DCs,
which showed that H. pylori-experienced DCs appear to
preferentially prime Treg over Th17 responses [50] and
fail to produce pro-inflammatory cytokines [51]. The
model of a predominantly tolerogenic role of DCs in the
context of H. pylori infection is further corroborated by
the demonstration that vaccine-induced protective immu-
nity can be improved by systemic DC depletion [36] and
by our finding that the lungs of neonatally infected mice
subjected to experimental asthma induction are populated
by semi-mature (and presumably tolerogenic) DCs [40].
B-cells exhibit immunoregulatory rather than
protective properties in the context of H. pylori
infection
H. pylori-infected patients are characterized by high
serum titers to H. pylori antigens, and serology is routi-
nely used to diagnose the infection. Being a mucosal
pathogen, H. pylori was initially suspected of triggering
potentially protective mucosal IgA responses. However,
early studies with mice lacking B-cells (μMT-/- mice) or
antibodies (IgA-/-) revealed that vaccine-induced protec-
tive immunity develops equally well in wild type and
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B-cell or antibody-deficient mice [24,52,53]. The results
challenged the dogma that extracellular mucosal patho-
gens are controlled by antibodies and was confirmed
again in a recent study introducing a novel and very
effective new adjuvant derived from mycobacterial cell
walls [36]. Subsequent work by Lycke and colleagues
demonstrated that antibodies are not only dispensable
for H. pylori clearance, but may even have detrimental
effects on the human host [52]. μMT-/- mice lacking B-
cells altogether spontaneously reduce H. pylori burdens,
but develop accelerated and aggravated gastritis [52].
Gene-targeting of the IL-10 and IgA-encoding genes
synergizes to clear the infection, i.e. IL-10-/-/IgA-/- mice
clear H. pylori infections better than IL-10-/- mice, both
under conditions of experimental infection of naive as
well as previously vaccinated mice [54]. The combined
results show rather unequivocally that B-cells impair
rather than promote immunity to H. pylori.
Figure 3 TLR-2-activated B-cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1
cells. Schematic representation of the events occurring in the course of Helicobacter-specific activation of B-cells at the site of infection (i.e. the
gastric mucosa) and/or in the draining mesenteric lymph nodes. Helicobacter TLR-2 ligands activate B-cells in a MyD88-dependent manner,
which leads to the expression and surface exposure of CD80, CD86 (together referred to as B7 molecules), the increased expression of CD40,
and the secretion of IL-10, IL-6 and moderate amounts of TNF-a (the latter is not shown here) as well as antibodies of the IgM and IgG2b
subclasses. The interaction of activated B-cells and naive T-cells induces T-cellular IL-10 expression and suppressive activity in a manner
dependent on a direct interaction between both cell types via CD40/CD40L, B7/CD28 and MHCII/TCR. IL-10 secreting T-cells are essential players
in the prevention of excessive Helicobacter-associated immunopathology. Adapted from [11].
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We have recently attempted to elucidate the signaling
pathways that play a role in B-cellular immunosuppression
in the context of H. pylori infection. Interestingly, we
found that B-cells exposed to Helicobacter extract pro-
duced large amounts of the regulatory cytokine IL-10 [11].
B-cell recognition of Helicobacter and the associated IL-10
production was entirely dependent on TLR2 and Myd88,
as B-cells from the respective knock-out mice did not pro-
duce IL-10. Helicobacter-exposed B-cells further acquired
the ability to efficiently induce IL-10 production in co-cul-
tured, naive CD4+ T-cells, thereby converting the T-cells
to T-regulatory-1 (Tr1)-like cells with suppressive activity.
In vivo studies using conditional knock-out mouse strains
revealed that IL-10 production by T-cells, but not B-cells,
was essential for the suppression of excessive gastric
immunopathology. On the other hand, B-cells lacking
Myd88 or TLR2 -in contrast to wild type B-cells- were
incapable of preventing the characteristic infection-asso-
ciated immunopathology of Myd88-/- or IL-10-/- strains
when adoptively co-transferred with Tr1 cells [11]. Taken
together, the results (summarized in Figure 3) suggest that
the B-cell/Tr-1 cell axis is essential for balancing the con-
trol of Helicobacter infection with the prevention of exces-
sive T-cell-driven gastric immunopathology.
Conclusions
H. pylori has co-evolved with its human host for at least
30.000 years [55]. In contrast to most other bacterial
pathogens, which temporarily cause virulent disease but
are then rapidly cleared upon the onset of a pathogen-spe-
cific adaptive immune response, H. pylori persists in its
host for decades, if not for life. This extraordinary ability
to thrive in the face of a robust and vigorous local and sys-
temic immune response is due to elaborate evolutionary
adaptations of H. pylori that allow the bacteria to not only
escape detection by pattern recognition receptors on
innate immune cells, but to also evade adaptive immunity.
The immunomodulatory properties of the pathogen repro-
gram the immune system towards immunological toler-
ance and assist the bacteria in establishing persistent
infection. A byproduct of H. pylori-specific immunomodu-
lation and immune tolerance is evident in Western socie-
ties that have largely eliminated the infection due to
reduced transmission rates, frequent use of antibiotics in
childhood and better sanitation. In these populations, the
rates of asthma, allergies and other chronic inflammatory
and auto-immune diseases have reached epidemic propor-
tions; the inverse correlation of the incidence of such dis-
eases and H. pylori infection rates is striking and deserves
further investigation. A better understanding of the signal-
ing pathways and molecular players targeted by H. pylori
to manipulate the host immune response and establish
and maintain persistence will be instrumental for improv-
ing rational H. pylori vaccine design and possibly for
exploiting H. pylori’s protective properties for asthma and
allergy prevention and treatment.
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